How does ozempic impact your salt cravings?

Does Ozempic reduce salt cravings?
Ozempic (semaglutide) slows gastric emptying and alters gut-brain signaling through GLP-1 receptors. These actions commonly reduce overall appetite and the drive for highly palatable foods, which many users describe as lower cravings for salty snacks. The effect is indirect rather than targeted at sodium taste perception.

Why do some people still crave salt on Ozempic?
Individual responses vary. A subset of users report persistent or even increased salt preference, possibly because semaglutide can promote mild dehydration or electrolyte shifts that prompt the body to seek sodium. Others notice no change at all. Factors such as diet, hydration status, and concurrent medications influence the outcome.

How long do changes in salt cravings last?
Cravings often decrease within the first 4–8 weeks as appetite suppression stabilizes. The reduction tends to persist while the patient continues treatment. When Ozempic is stopped, salt cravings typically return to baseline within weeks as GLP-1 signaling normalizes.

Can Ozempic cause increased thirst that mimics salt craving?
Yes. Because semaglutide slows gastric emptying and can raise blood glucose temporarily during dose escalation, some patients experience dry mouth or increased thirst. This sensation is frequently misinterpreted as a desire for salty foods rather than plain water.

What should patients monitor when salt cravings change?
Track daily sodium intake, hydration, and blood pressure. Excessive salt consumption can counteract some cardiovascular benefits of weight loss. Patients with hypertension or kidney disease should discuss any marked increase in salt desire with their prescriber, as dose adjustment or additional monitoring may be warranted.

Are there alternatives if salt cravings remain problematic?
Lifestyle measures such as increasing water intake, eating potassium-rich foods, and spacing meals can blunt residual cravings. If cravings stay intense, switching to a different GLP-1 agent or adding behavioral strategies may help; these decisions should be made with a clinician.